{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"description":"Percentage of participants with Overall Survival in response to Dd-R in newly diagnosed multiple myeloma patients with active disease. Overall survival is time from study entry to death of any cause.","groups":[{"description":"Induction Phase Followed by Maintenance Therapy.\n\nPatients received lenalidomide 25 mg orally on days 1-21, dexamethasone 40 mg orally on days on 1-4, and Pegylated Liposomal Doxorubicin (PLD) 40 mg/m\\^2 intravenously on day 1 (reduced to 30 mg/m\\^2 after the initial 29 patients were treated). Cycles were repeated every 28 days.\n\nAt the best response (4-8 cycles of induction), patients could proceed with either high-dose therapy or maintenance with lenalidomide and dexamethasone at the tolerated doses on the same schedule until disease progression.\n\nDd-R: Lenalidomide (Revlimid®) combined with Pegylated Liposomal Doxorubicin (Doxil®) and Dexamethasone (Decadron®) as outlined in the Detailed Description.","id":"OG000","title":"Induction and Maintenance Therapy"}],"paramType":"NUMBER","populationDescription":"All participants","reportingStatus":"POSTED","timeFrame":"24 Months","title":"2 Year Overall Survival (OS) Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}